⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ethylene SCHEMBL30556369 | 0.63 | — | — | |
| Ethylene SCHEMBL30556368 | 0.63 | — | — | |
| Ethylene SCHEMBL7596303 | 0.63 | — | — | |
| Ethylene SCHEMBL1770 | 0.63 | — | — | |
| Ethylene SCHEMBL1332643 | 0.63 | — | — | |
| Ethylene SCHEMBL675055 | 0.63 | — | — | |
| Ethylene SCHEMBL1331580 | 0.63 | — | — | |
| Ethylene SCHEMBL8323678 | 0.63 | — | — | |
| Ethylene SCHEMBL9863791 | 0.63 | — | — | |
| Ethylene SCHEMBL5598258 | 0.63 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023129976-A1 | SALT AND SOLID FORMS OF KETANSERIN | TERRAN BIOSCIENCES, INC. (US) | 2023-07-06 | — | — | WO | disclosed |
| US-20180344803-A1 | Methods and Compositions For the Treatment of Proteinuric Diseases | THE GENERAL HOSPITAL CORPORATION | 2018-12-06 | — | — | US | disclosed |
| US-20160296592-A1 | Methods and Compositions for the Treatment of Proteinuric Diseases | THE GENERAL HOSPITAL CORPORATION | 2016-10-13 | — | — | US | disclosed |
| US-9345739-B2 | Methods and compositions for the treatment of proteinuric diseases | THE GENERAL HOSPITAL CORPORATION (US) | 2016-05-24 | — | — | US | disclosed |
| EP-2730282-A1 | Methods and compositions for the treatment of proteinuric diseases | The General Hospital Corporation (US) | 2014-05-14 | — | — | EP | disclosed |
| US-20100297139-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF PROTEINURIC DISEASES | THE GENERAL HOSPITAL CORPORATION | 2010-11-25 | — | — | US | disclosed |
| US-20100048536-A1 | Novel Substituted Diaryl Azepine Derivatives as Integrin Ligands | GENESTE HERVE | 2010-02-25 | — | — | US | disclosed |
| WO-2009061448-A9 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF PROTEINURIC DISEASES | THE GENERAL HOSPITAL CORPORATION (US) | 2009-08-13 | — | — | WO | disclosed |
| US-20080221082-A1 | Ligands of Integrin Receptors | ABBOTT GMBH & CO. KG (DE) | 2008-09-11 | — | — | US | disclosed |
| US-7279468-B2 | Integrin ligands | ABBOTT GMBH & CO. KG (DE) | 2007-10-09 | — | — | US | disclosed |
| US-7105508-B1 | Integrin receptors antagonists | ABBOTT GMBH & CO. KG (DE) | 2006-09-12 | — | — | US | disclosed |
| US-20040077638-A1 | Novel integrin receptor antagonists | BASF AKTIENGESELLCHAFT (DE) | 2004-04-22 | — | — | US | disclosed |
| US-20040063934-A1 | Integrin ligands | ABBVIE DEUTSCHLAND GMBH & CO KG (DE) | 2004-04-01 | — | — | US | disclosed |